Aclaris Therapeutics Inc (ACRS)
22.95
-0.88 -3.69%
NASDAQ
May 7, 20:00
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 6.482M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -1.20 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -51.02M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 18.61% |
| Profit Margin (Quarterly) | -833.7% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 1.195B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 150.61 |
| PE Ratio | -- |
| Price to Book Value | 31.75 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.2829 |
| Free Cash Flow (Quarterly) | -8.865M |
| Return on Equity | Upgrade |
View All ACRS News
News
-
WireHeadlineTime (ET)
-
MT Newswires05/07 09:17
-
Yahoo05/07 08:35
-
SA Breaking News05/07 07:39
-
MT Newswires05/07 07:04
-
Globe Newswire05/07 07:00
-
Yahoo04/29 17:02
-
Yahoo04/26 01:39
-
MT Newswires04/21 09:25
-
Yahoo03/18 18:02
-
SA Breaking News03/15 15:19
-
MT Newswires03/15 09:10
-
MT Newswires03/15 07:44
-
Globe Newswire03/15 07:00
-
MT Newswires03/04 09:57
-
SA Breaking News02/25 07:27
-
MT Newswires02/25 07:06
-
Globe Newswire02/25 07:00
-
SA Breaking News02/22 12:50
-
Globe Newswire02/22 07:00
-
Globe Newswire02/10 07:00
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 11/04/2021 17:00 | Earnings Calls | Q3 2021 Earnings Call |
| 08/06/2021 00:00 | Earnings Results | Q2 2021 Earnings Results |
| 02/25/2021 00:00 | Earnings Results | Q4 2020 Earnings Results |
| 11/04/2020 00:00 | Earnings Results | Q3 2020 Earnings Results |
| 08/07/2020 00:00 | Earnings Results | Q2 2020 Earnings Results |
| 06/04/2020 09:00 EDT | AGM | 2019 Annual General Meeting |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are ATI-450, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
- URL: https://www.aclaristx.com
- Investor Relations URL: https://www.aclaristx.com/#!investors/juser
- HQ State/Province: Pennsylvania
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Blend
- Next Earnings Release: Aug. 06, 2021
- Last Earnings Release: Feb. 25, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 22.95 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| PTH | Invesco DWA Healthcare Momentum ETF | 2.82% |
| DWMC | AdvisorShares Dorsey Wright Micro-Cp ETF | 1.62% |
| DWAS | Invesco DWA SmallCap Momentum ETF | 1.31% |
| LGSCX | QS US Small Capitalization Equity FI | 0.70% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ACRS Tweets Stocktwits
Advertisement
